Open Access iconOpen Access

ARTICLE

crossmark

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

CHIWEN BU1,2, LIGANG ZHAO1, LISHAN WANG1, ZEQIAN YU1, JIAHUA ZHOU1,*

1 Department of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China
2 School of Medicine, Southeast University, Nanjing, 210009, China

* Corresponding Author: JIAHUA ZHOU. Email: email

Oncology Research 2023, 31(4), 495-503. https://doi.org/10.32604/or.2023.029309

Abstract

Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the mTORC2 obligate subunit Rictor sensitized pancreatic cancer cells to the PARP inhibitor olaparib. Mechanistically, we showed that mTORC2 positively regulates homologous recombination (HR) repair by modulating BRCA1 recruitment to DNA double-strand breaks (DSBs). In addition, we confirmed that combination treatment with the mTORC2 inhibitor PP242 and the PARP inhibitor olaparib synergistically inhibited pancreatic cancer growth in vivo. Thus, this study provides a novel target and strategy for optimizing PARP inhibitor efficiency in pancreatic cancers.

Graphical Abstract

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

Keywords


Cite This Article

APA Style
BU, C., ZHAO, L., WANG, L., YU, Z., ZHOU, J. (2023). Mtorc2 promotes pancreatic cancer progression and parp inhibitor resistance. Oncology Research, 31(4), 495-503. https://doi.org/10.32604/or.2023.029309
Vancouver Style
BU C, ZHAO L, WANG L, YU Z, ZHOU J. Mtorc2 promotes pancreatic cancer progression and parp inhibitor resistance. Oncol Res. 2023;31(4):495-503 https://doi.org/10.32604/or.2023.029309
IEEE Style
C. BU, L. ZHAO, L. WANG, Z. YU, and J. ZHOU "mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance," Oncol. Res., vol. 31, no. 4, pp. 495-503. 2023. https://doi.org/10.32604/or.2023.029309



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 900

    View

  • 434

    Download

  • 0

    Like

Share Link